Hansoh Pharmaceutical Group Co., Ltd. is a holding company, which engages in the research and development, production, and sale of a series of pharmaceutical products. The company is headquartered in Shanghai, Shanghai and currently employs 9,313 full-time employees. The company went IPO on 2019-06-14. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The firm mainly conducts its business in the domestic market.
03692.HK stock price ended at $37.24 on 木曜日, after dropping 1.90%
On the latest trading day Feb 12, 2026, the stock price of 03692.HK fell by 1.90%, dropping from $37.50 to $37.24. During the session, the stock saw a volatility of 4.18%, with prices oscillating between a daily low of $36.36 and a high of $37.88. On the latest trading day, the trading volume for 03692.HK rose by 1.7M shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 7.4M shares were traded, with a market value of approximately $221.4B.